1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: Amgen positions for obesity and diabetes; BMS returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer’s crown?; Japan pharma firms cut jobs; and Sun Pharma seeks GLP-1 partner.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 August 2024, including: Amgen, Inc. positions for obesity and diabetes; Bristol Myers Squibb Company returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer AG’s crown?; Japan pharma firms cut jobs; and Sun Pharmaceutical Industries Ltd. seeks GLP-1 partner. 

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode: 

(Also see "Amgen Gets Into Position For MariTide Development" - Scrip, 6 August, 2024.)

(Also see "BMS Returns TIGIT Bispecific To Agenus Amid Pipeline Reshuffle" - Scrip, 5 August, 2024.)

(Also see "Kerendia Could Be Next Jewel In Bayer's Pharma Crown" - Scrip, 6 August, 2024.)

(Also see "Japan Pharma Layoffs: Takeda And Others Implementing Broad Cuts" - Scrip, 8 August, 2024.)

(Also see "Sun Seeks Partner For GLP-I Asset, Legal Challenge Clouds Alopecia Drug Launch" - Scrip, 5 August, 2024.)

Citeline · Scrip's Five Must-Know Things - 13 August 2024

Open Media

More from Alimentary/Metabolic

Vertex Ends One Type 1 Diabetes Cell Therapy, Shifts Focus To Another

 
• By Joseph Haas

Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.

Novo Scores Cardio Wins But Lilly Still Tipped To Take GLP-1 Crown

 
• By Andrew McConaghie

Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.

Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry

 
• By Andrew McConaghie

The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.

Unicycive Approaches Its First Approval, But In A Competitive Space

 
• By Jessica Merrill

The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.

More from Therapy Areas

AbbVie On A STEAP Learning Curve In ADCs

 
• By Andrew McConaghie

Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By Kevin Grogan

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure

 
• By Alaric DeArment

The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.